Thrombosis Science and Venous Thromboembolism Management

Each population has a distinct combination of risk factors and baseline thrombosis incidence, so a single generic risk tool would not accurately capture risk in every setting. Surgical risk relates heavily to procedure type and duration, medical inpatient risk relates to acute illness and immobility, and oncology risk relates to tumor type and treatment. Using population-specific validated tools improves the accuracy of risk stratification and subsequent prophylaxis decisions.

Inadequate thromboprophylaxis can lead to deep vein thrombosis or pulmonary embolism, both of which carry short-term morbidity and mortality risk as well as potential long-term complications such as post-thrombotic syndrome. Hospital-acquired venous thromboembolism remains a recognized preventable cause of patient harm. This underscores the importance of applying validated risk-assessment tools consistently across relevant patient populations.

Thrombosis risk should generally be reassessed whenever a patient's clinical status changes significantly, such as with new immobility, an additional diagnosis, or a change in treatment plan, rather than only at admission. Regular reassessment ensures prophylaxis decisions remain aligned with the patient's current risk level throughout their stay. Healthcare professionals should incorporate this reassessment into routine clinical review during hospitalization.